Relmada Therapeutics
RLMD
103 hedge funds and large institutions have $589M invested in Relmada Therapeutics in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 10 closing their positions.
570% more call options, than puts
Call options by funds: $3.66M | Put options by funds: $546K
270% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 10
136% more capital invested
Capital invested by funds: $249M → $589M (+$340M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more funds holding
Funds holding: 78 → 103 (+25)
10.36% more ownership
Funds ownership: 70.41% → 80.77% (+10%)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
Top Buyers
| 1 |
VA
VR Adviser
New York
|
+$22.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$17.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$13.9M |
| 4 |
Millennium Management
New York
|
+$10.6M |
| 5 |
SSC
Spruce Street Capital
New York
|
+$10.3M |
Top Sellers
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$7.64M |
| 2 |
Corient Private Wealth
Miami,
Florida
|
-$3.4M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.8M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.56M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.4M |
RLMD Hedge Fund Activity: Q1 2026 in Review
103 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2026, worth a combined $589M — up 136% from $249M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new RLMD positions and 10 closed out — a net gain of 27 holders — while 27 added to existing stakes and 25 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $22.9M. The largest seller was Braidwell, exiting entirely with an estimated $7.64M sold.
- 103 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2026, up from 78 in Q4 2025.
- Funds reported $589M of Relmada Therapeutics stock for Q1 2026, up 136% quarter-over-quarter.
- 37 funds opened new Relmada Therapeutics positions in Q1 2026 and 10 closed out, a net change of +27 holders.
- The largest Relmada Therapeutics buyer in Q1 2026 was VR Adviser, an estimated $22.9M added.
- The largest Relmada Therapeutics seller in Q1 2026 was Braidwell, an estimated $7.64M sold.
Based on aggregated 13F filings for Q1 2026.